Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-10-2019 | Multiple Myeloma | Original Article

Flow Cytometric Evaluation of Traditional and Novel Surface Markers for the Diagnosis of Plasma Cell Dyscrasias

Authors: Dominik F. Draxler, Lisa M. Wutzlhofer, Georg Slavka, Wolfgang Hübl, Heinz Ludwig, Martin Schreder, John Reynolds, Martin Willheim

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 4/2019

Abstract

Increasing interest has been expressed for flow cytometric immunophenotyping for diagnosis and monitoring in plasma cell dyscrasias over the last decades. The aim of this investigation was to compare the expression strength of various cell surface markers used traditionally or currently under investigation on normal and abnormal PC populations. We enrolled 295 consecutive patients undergoing bone marrow aspiration in the workup of monoclonal gammopathies, selecting 54 normal and 241 abnormal PC populations via flow cytometry to characterize the expression of CD45, CD38, CD138, CD19, CD56, CD20, CD27, CD28, CD81, CD117 and CD200 on the cell surface of PCs. We observed significant differences in the expression strength of all assessed markers between normal and abnormal PC populations in all markers except for CD20. While none of them was conclusive on its own, the combination of CD81 positivity and CD117 negativity was present in 98.1% of normal PC populations tested. In contrast, particularly CD117 positivity, but also CD81 negativity was indicative of an abnormal PC phenotype. Our results highlight the descriptive value of CD81 and CD117 for the allocation of bone marrow PCs to a normal or abnormal phenotype.

Available only for authorised users

Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 18:1860–1873CrossRef

Rajkumar SV (2013) Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 3:226–235

Chesi M, Bergsagel PL (2013) Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol 3:313–323CrossRef

Raja KR, Kovarova L, Hajek R (2010) Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 3:334–351CrossRef

Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 11:1046–1060CrossRef

Kyle RA, Rajkumar SV (2008) Multiple myeloma. Blood 6:2962–2972CrossRef

Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC (2009) Multiple myeloma. Lancet 9686:324–339CrossRef

Willrich MA, Katzmann JA (2016) Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias. Clin Chem Lab Med 6:907–919

Paiva B, Almeida J, Perez-Andres M, Mateo G, Lopez A, Rasillo A et al (2010) Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytom B Clin Cytom 4:239–252

10.

Tran DN, Smith SA, Brown DA, Parker AJ, Joseph JE, Armstrong N et al (2017) Polychromatic flow cytometry is more sensitive than microscopy in detecting small monoclonal plasma cell populations. Cytom B Clin Cytom 2:136–144CrossRef

11.

Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H et al (2008) Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 3:431–438CrossRef

12.

Paiva B, Vidriales MB, Rosinol L, Martinez-Lopez J, Mateos MV, Ocio EM et al (2013) A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia 10:2056–2061CrossRef

13.

Ocqueteau M, Orfao A, Almeida J, Blade J, Gonzalez M, Garcia-Sanz R et al (1998) Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 6:1655–1665

14.

Kobayashi S, Hyo R, Amitani Y, Tanaka M, Hashimoto C, Sakai R et al (2006) Four-color flow cytometric analysis of myeloma plasma cells. Am J Clin Pathol 6:908–915CrossRef

15.

Harada H, Kawano MM, Huang N, Harada Y, Iwato K, Tanabe O et al (1993) Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 10:2658–2663CrossRef

16.

Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ et al (2003) CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 3:1070–1071CrossRef

17.

Zandecki M, Facon T, Bernardi F, Izydorczyk V, Dupond L, Francois M et al (1995) CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance. J Clin Pathol 6:548–552CrossRef

18.

Guikema JE, Hovenga S, Vellenga E, Conradie JJ, Abdulahad WH, Bekkema R et al (2003) CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br J Haematol 1:36–43CrossRef

19.

Katayama Y, Sakai A, Oue N, Asaoku H, Otsuki T, Shiomomura T et al (2003) A possible role for the loss of CD27–CD70 interaction in myelomagenesis. Br J Haematol 2:223–234CrossRef

20.

Pellat-Deceunynck C, Bataille R, Robillard N, Harousseau JL, Rapp MJ, Juge-Morineau N et al (1994) Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 8:2597–2603CrossRef

21.

Robillard N, Jego G, Pellat-Deceunynck C, Pineau D, Puthier D, Mellerin MP et al (1998) CD28, a marker associated with tumoral expansion in multiple myeloma. Clin Cancer Res 6:1521–1526

22.

Ocqueteau M, Orfao A, Garcia-Sanz R, Almeida J, Gonzalez M, San Miguel JF (1996) Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. Br J Haematol 3:489–493CrossRef

23.

Bataille R, Pellat-Deceunynck C, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P (2008) CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. Leuk Res 3:379–382CrossRef

24.

Lin P, Owens R, Tricot G, Wilson CS (2004) Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 4:482–488CrossRef

25.

Olteanu H, Harrington AM, Hari P, Kroft SH (2011) CD200 expression in plasma cell myeloma. Br J Haematol 3:408–411CrossRef

26.

Paiva B, Gutierrez NC, Chen X, Vidriales MB, Montalban MA, Rosinol L et al (2012) Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia 8:1862–1869CrossRef

27.

Flores-Montero J, de Tute R, Paiva B, Perez JJ, Bottcher S, Wind H et al (2016) Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma. Cytom B Clin Cytom 1:61–72CrossRef

28.

Porwit A (2013) Immunophenotyping of selected hematologic disorders–focus on lymphoproliferative disorders with more than one malignant cell population. Int J Lab Hematol. 3:275–282CrossRef

29.

Cannizzo E, Carulli G, Del Vecchio L, Ottaviano V, Bellio E, Zenari E et al (2012) The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model. Am J Clin Pathol 3:377–386CrossRef

30.

Flanders A, Stetler-Stevenson M, Landgren O (2013) Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Blood 6:1088–1089CrossRef

31.

Bataille R, Jego G, Robillard N, Barille-Nion S, Harousseau JL, Moreau P et al (2006) The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy. Haematologica 9:1234–1240

32.

Pellat-Deceunynck C, Bataille R (2004) Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells Mol Dis 2:293–301CrossRef

33.

Robillard N, Pellat-Deceunynck C, Bataille R (2005) Phenotypic characterization of the human myeloma cell growth fraction. Blood 12:4845–4848CrossRef

34.

Moreau P, Robillard N, Jego G, Pellat C, Le Gouill S, Thoumi S et al (2006) Lack of CD27 in myeloma delineates different presentation and outcome. Br J Haematol 2:168–170CrossRef

35.

Cannizzo E, Bellio E, Sohani AR, Hasserjian RP, Ferry JA, Dorn ME et al (2010) Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology. Cytom B Clin Cytom 4:231–238

36.

Tohami T, Drucker L, Shapiro H, Radnay J, Lishner M (2007) Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential. FASEB J 3:691–699CrossRef

37.

Barrena S, Almeida J, Yunta M, Lopez A, Fernandez-Mosteirin N, Giralt M et al (2005) Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia 8:1376–1383CrossRef

38.

Luo RF, Zhao S, Tibshirani R, Myklebust JH, Sanyal M, Fernandez R et al (2010) CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. Hum Pathol 2:271–280CrossRef

39.

Tembhare PR, Yuan CM, Venzon D, Braylan R, Korde N, Manasanch E et al (2014) Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res 3:371–376CrossRef

40.

Alapat D, Coviello-Malle J, Owens R, Qu P, Barlogie B, Shaughnessy JD et al (2012) Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. Am J Clin Pathol 1:93–100CrossRef

41.

Olteanu H, Harrington AM, Kroft SH (2012) CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma. Am J Clin Pathol 6:867–876CrossRef

42.

Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E et al (2006) CD200 is a new prognostic factor in multiple myeloma. Blood 13:4194–4197CrossRef

Title: Flow Cytometric Evaluation of Traditional and Novel Surface Markers for the Diagnosis of Plasma Cell Dyscrasias
Authors: Dominik F. Draxler
Lisa M. Wutzlhofer
Georg Slavka
Wolfgang Hübl
Heinz Ludwig
Martin Schreder
John Reynolds
Martin Willheim
Publication date: 01-10-2019
Publisher: Springer India
Keyword: Multiple Myeloma
Published in: Indian Journal of Hematology and Blood Transfusion / Issue 4/2019
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-019-01105-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

Evaluation of Cytogenetic Abnormalities in Patients with Acute Lymphoblastic Leukemia

Performance Evaluation of Automated Immunohematology Analyzer IH-500 for Blood Bank Testing

Inhibition of γ/β Globin Gene Switching in CD 34+ Derived Erythroid Cells by BCL11A RNA Silencing

Primary Plasma Cell Leukemia: A Retrospective Study of a Rare Disease From Tertiary Cancer Centre From India

Effect of Frequency of Platelet Apheresis on Coagulation Function in Donors: A Prospective Cohort Study

Factors Influencing the Safety and Efficiency of Antifungal Prophylaxis with Posaconazole in Children with Hematological Diseases: From Genetics to Polypharmacotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer